Does the media refer more to AUPH or ALT?

In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 3 articles in the media. Aurinia Pharmaceuticals' average media sentiment score of 0.20 beat Altimmune's score of 0.12 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Altimmune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BCRX or ALT?

In the previous week, BioCryst Pharmaceuticals had 1 more articles in the media than Altimmune. MarketBeat recorded 4 mentions for BioCryst Pharmaceuticals and 3 mentions for Altimmune. BioCryst Pharmaceuticals' average media sentiment score of 0.23 beat Altimmune's score of 0.12 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Altimmune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, ALT or VCEL?

Vericel has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Altimmune $40K 12,692.43 -$88.09M -$0.78 N/A Vericel $306.30M 6.70 $16.52M $0.47 85.32

Is ALT or VCEL more profitable?

Vericel has a net margin of 7.91% compared to Altimmune's net margin of 0.00%. Vericel's return on equity of 6.91% beat Altimmune's return on equity. Company Net Margins Return on Equity Return on Assets Altimmune N/A -31.41% -26.96% Vericel 7.91% 6.91% 5.02%

Does the media favor ALT or VCEL?

In the previous week, Altimmune had 1 more articles in the media than Vericel. MarketBeat recorded 3 mentions for Altimmune and 2 mentions for Vericel. Vericel's average media sentiment score of 0.99 beat Altimmune's score of 0.12 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Vericel 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, ALT or PHVS?

Altimmune has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Altimmune $40K 12,692.43 -$88.09M -$0.78 N/A Pharvaris N/A N/A -$198.79M -$3.05 N/A

Is ALT or PHVS more profitable?

Altimmune's return on equity of -31.41% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Altimmune N/A -31.41% -26.96% Pharvaris N/A -61.40% -56.00%

Does the media prefer ALT or PHVS?

In the previous week, Pharvaris had 13 more articles in the media than Altimmune. MarketBeat recorded 16 mentions for Pharvaris and 3 mentions for Altimmune. Pharvaris' average media sentiment score of 0.27 beat Altimmune's score of 0.12 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Pharvaris 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings and valuation, BHVN or ALT?

Altimmune has higher revenue and earnings than Biohaven. Altimmune is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$4.64 N/A Altimmune $40K 12,692.43 -$88.09M -$0.78 N/A

Is BHVN or ALT more profitable?

Altimmune's return on equity of -31.41% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -1,328.94% -138.27% Altimmune N/A -31.41% -26.96%

Does the media refer more to BHVN or ALT?

In the previous week, Biohaven had 3 more articles in the media than Altimmune. MarketBeat recorded 6 mentions for Biohaven and 3 mentions for Altimmune. Biohaven's average media sentiment score of 0.44 beat Altimmune's score of 0.12 indicating that Biohaven is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Altimmune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Altimmune (ALT) Competitors

$2.61 +0.01 (+0.38%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.62 +0.02 (+0.57%)

As of 10/9/2026 07:46 PM Eastern

Compare

ALT vs. AUPH, BCRX, VCEL, PHVS, and BHVN

Should you buy Altimmune stock or one of its competitors? Altimmune's main competitors and comparable companies include Aurinia Pharmaceuticals (AUPH), BioCryst Pharmaceuticals (BCRX), Vericel (VCEL), Pharvaris (PHVS), and Biohaven (BHVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Altimmune compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Altimmune (NASDAQ:ALT) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Aurinia Pharmaceuticals has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.06, suggesting that its share price is 94% less volatile than the broader market.

Aurinia Pharmaceuticals presently has a consensus target price of $17.67, suggesting a potential upside of 6.11%. Altimmune has a consensus target price of $14.33, suggesting a potential upside of 449.17%. Given Altimmune's stronger consensus rating and higher probable upside, analysts clearly believe Altimmune is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Altimmune's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Altimmune	N/A	-31.41%	-26.96%

In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 3 articles in the media. Aurinia Pharmaceuticals' average media sentiment score of 0.20 beat Altimmune's score of 0.12 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Altimmune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aurinia Pharmaceuticals has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.83	$287.20M	$2.29	7.27
Altimmune	$40K	12,692.43	-$88.09M	-$0.78	N/A

Summary

Aurinia Pharmaceuticals beats Altimmune on 11 of the 16 factors compared between the two stocks.

How does Altimmune compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Altimmune (NASDAQ:ALT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Altimmune has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. Altimmune's return on equity of -31.41% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
Altimmune	N/A	-31.41%	-26.96%

BioCryst Pharmaceuticals has higher revenue and earnings than Altimmune. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.50	$263.86M	-$1.50	N/A
Altimmune	$40K	12,692.43	-$88.09M	-$0.78	N/A

BioCryst Pharmaceuticals currently has a consensus price target of $20.50, suggesting a potential upside of 139.77%. Altimmune has a consensus price target of $14.33, suggesting a potential upside of 449.17%. Given Altimmune's stronger consensus rating and higher probable upside, analysts clearly believe Altimmune is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, BioCryst Pharmaceuticals had 1 more articles in the media than Altimmune. MarketBeat recorded 4 mentions for BioCryst Pharmaceuticals and 3 mentions for Altimmune. BioCryst Pharmaceuticals' average media sentiment score of 0.23 beat Altimmune's score of 0.12 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Altimmune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCryst Pharmaceuticals has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Altimmune has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market.

Summary

BioCryst Pharmaceuticals and Altimmune tied by winning 8 of the 16 factors compared between the two stocks.

How does Altimmune compare to Vericel?

Altimmune (NASDAQ:ALT) and Vericel (NASDAQ:VCEL) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Vericel has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	12,692.43	-$88.09M	-$0.78	N/A
Vericel	$306.30M	6.70	$16.52M	$0.47	85.32

In the previous week, Altimmune had 1 more articles in the media than Vericel. MarketBeat recorded 3 mentions for Altimmune and 2 mentions for Vericel. Vericel's average media sentiment score of 0.99 beat Altimmune's score of 0.12 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.1% of Altimmune shares are owned by institutional investors. 1.6% of Altimmune shares are owned by company insiders. Comparatively, 7.6% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Altimmune currently has a consensus target price of $14.33, suggesting a potential upside of 449.17%. Vericel has a consensus target price of $58.40, suggesting a potential upside of 45.64%. Given Altimmune's stronger consensus rating and higher possible upside, equities analysts clearly believe Altimmune is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Altimmune has a beta of 0.06, suggesting that its share price is 94% less volatile than the broader market. Comparatively, Vericel has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market.

Vericel has a net margin of 7.91% compared to Altimmune's net margin of 0.00%. Vericel's return on equity of 6.91% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	N/A	-31.41%	-26.96%
Vericel	7.91%	6.91%	5.02%

Summary

Vericel beats Altimmune on 10 of the 16 factors compared between the two stocks.

How does Altimmune compare to Pharvaris?

Altimmune (NASDAQ:ALT) and Pharvaris (NASDAQ:PHVS) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Pharvaris had 13 more articles in the media than Altimmune. MarketBeat recorded 16 mentions for Pharvaris and 3 mentions for Altimmune. Pharvaris' average media sentiment score of 0.27 beat Altimmune's score of 0.12 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharvaris	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

78.1% of Altimmune shares are owned by institutional investors. 1.6% of Altimmune shares are owned by company insiders. Comparatively, 11.8% of Pharvaris shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Altimmune has a beta of 0.06, indicating that its share price is 94% less volatile than the broader market. Comparatively, Pharvaris has a beta of -2.46, indicating that its share price is 346% less volatile than the broader market.

Altimmune's return on equity of -31.41% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	N/A	-31.41%	-26.96%
Pharvaris	N/A	-61.40%	-56.00%

Altimmune has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	12,692.43	-$88.09M	-$0.78	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A

Altimmune currently has a consensus target price of $14.33, indicating a potential upside of 449.17%. Pharvaris has a consensus target price of $58.60, indicating a potential upside of 88.42%. Given Altimmune's higher possible upside, research analysts clearly believe Altimmune is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Altimmune beats Pharvaris on 9 of the 14 factors compared between the two stocks.

How does Altimmune compare to Biohaven?

Biohaven (NYSE:BHVN) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Altimmune's return on equity of -31.41% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,328.94%	-138.27%
Altimmune	N/A	-31.41%	-26.96%

In the previous week, Biohaven had 3 more articles in the media than Altimmune. MarketBeat recorded 6 mentions for Biohaven and 3 mentions for Altimmune. Biohaven's average media sentiment score of 0.44 beat Altimmune's score of 0.12 indicating that Biohaven is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Altimmune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biohaven presently has a consensus price target of $18.69, suggesting a potential upside of 54.38%. Altimmune has a consensus price target of $14.33, suggesting a potential upside of 449.17%. Given Altimmune's stronger consensus rating and higher possible upside, analysts plainly believe Altimmune is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Biohaven has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.06, meaning that its share price is 94% less volatile than the broader market.

Altimmune has higher revenue and earnings than Biohaven. Altimmune is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A
Altimmune	$40K	12,692.43	-$88.09M	-$0.78	N/A

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 13.8% of Biohaven shares are owned by insiders. Comparatively, 1.6% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Biohaven and Altimmune tied by winning 7 of the 14 factors compared between the two stocks.

Get Altimmune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALT vs. The Competition

Export

Metric	Altimmune	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$505.75M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-3.35	13.42	274.15	26.16
Price / Sales	12,692.43	1,234.38	635.98	113.06
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	1.31	17.17	11.21	6.34
Net Income	-$88.09M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-4.40%	-1.33%	-0.90%	-1.41%
1 Month Performance	-20.67%	-8.44%	-4.44%	-3.48%
1 Year Performance	-33.42%	14.02%	6.96%	1.16%

Altimmune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALT Altimmune	2.5411 of 5 stars	$2.61 +0.4%	$14.33 +449.2%	-34.8%	$505.75M	$40K	N/A	57
AUPH Aurinia Pharmaceuticals	3.1581 of 5 stars	$15.72 -0.7%	$17.67 +12.4%	+43.3%	$2.11B	$283.05M	6.86	128	News Coverage
BCRX BioCryst Pharmaceuticals	2.9705 of 5 stars	$8.10 -0.9%	$20.50 +153.1%	+17.9%	$2.09B	$874.84M	N/A	435
VCEL Vericel	4.2926 of 5 stars	$41.07 +2.3%	$58.40 +42.2%	+22.4%	$2.06B	$276.26M	87.38	398
PHVS Pharvaris	3.3605 of 5 stars	$30.49 -2.2%	$59.87 +96.3%	+36.2%	$2.04B	N/A	N/A	148	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALT) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Altimmune (ALT) Competitors

ALT vs. AUPH, BCRX, VCEL, PHVS, and BHVN

How does Altimmune compare to Aurinia Pharmaceuticals?

Summary

How does Altimmune compare to BioCryst Pharmaceuticals?

Summary

How does Altimmune compare to Vericel?

Summary

How does Altimmune compare to Pharvaris?

Summary

How does Altimmune compare to Biohaven?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALT vs. The Competition

Altimmune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Altimmune (ALT) Competitors

ALT vs. AUPH, BCRX, VCEL, PHVS, and BHVN

How does Altimmune compare to Aurinia Pharmaceuticals?

Which has more volatility & risk, AUPH or ALT?

Do analysts recommend AUPH or ALT?

Do insiders & institutionals have more ownership in AUPH or ALT?

Is AUPH or ALT more profitable?

Does the media refer more to AUPH or ALT?

Which has preferable valuation & earnings, AUPH or ALT?

Summary

How does Altimmune compare to BioCryst Pharmaceuticals?

Is BCRX or ALT more profitable?

Which has higher earnings and valuation, BCRX or ALT?

Do analysts rate BCRX or ALT?

Do institutionals & insiders believe in BCRX or ALT?

Does the media favor BCRX or ALT?

Which has more volatility & risk, BCRX or ALT?

Summary

How does Altimmune compare to Vericel?

Which has higher earnings & valuation, ALT or VCEL?

Does the media favor ALT or VCEL?

Do institutionals and insiders hold more shares of ALT or VCEL?

Do analysts prefer ALT or VCEL?

Which has more risk & volatility, ALT or VCEL?

Is ALT or VCEL more profitable?

Summary

How does Altimmune compare to Pharvaris?

Does the media prefer ALT or PHVS?

Do insiders and institutionals believe in ALT or PHVS?

Which has more risk & volatility, ALT or PHVS?

Is ALT or PHVS more profitable?

Which has preferable earnings & valuation, ALT or PHVS?

Do analysts rate ALT or PHVS?

Summary

How does Altimmune compare to Biohaven?

Is BHVN or ALT more profitable?

Does the media refer more to BHVN or ALT?

Do analysts prefer BHVN or ALT?

Which has more risk & volatility, BHVN or ALT?

Which has better earnings and valuation, BHVN or ALT?

Do insiders & institutionals hold more shares of BHVN or ALT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALT vs. The Competition

Altimmune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools